Adjuvanted varicella zoster vaccine - Dynavax Technologies
Alternative Names: Adjuvanted varicella zoster virus recombinant vaccine - Dynavax Technologies; Chickenpox vaccine - Dynavax Technologies; Z-1018Latest Information Update: 30 Oct 2025
At a glance
- Originator Dynavax Technologies
- Class Subunit vaccines; Synthetic vaccines; Varicella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Herpes zoster
- No development reported Varicella zoster virus infections
Most Recent Events
- 21 Oct 2025 Adverse events and immunogenicity data from a phase I/II trial in Herpes zoster released by Dynavax Technologies
- 21 Aug 2025 Adverse events and immunogenicity data from a phase-I/II clinical trials in Herpes zoster released by Dynavax Technologies
- 28 Feb 2025 No recent reports of development identified for phase-I development in Varicella-zoster-virus-infections(Prevention) in USA (Parenteral)